Size | Price | Stock | Qty |
---|---|---|---|
25mg |
|
||
50mg |
|
||
100mg |
|
||
250mg |
|
||
500mg |
|
||
Other Sizes |
|
Purity: ≥98%
Bobcat339 HCl is a novel and potent cytosine-based TET enzyme inhibitor with IC50 of 33 μM (TET1) and 73 μM (TET2). Bobcat339 has mid-μM inhibitor activity against TET1 and TET2, but does not inhibit the DNA methyltransferase, DNMT3a. In silico modeling of the TET enzyme active site is used to rationalize the activity of Bobcat339 and other cytosine-based inhibitors. These new molecular tools will be useful to the field of epigenetics and serve as a starting point for new therapeutics that target DNA methylation and gene transcription. It is useful to the field of epigenetics and serves as a starting point for new therapeutics that target DNA methylation and gene transcription.
Targets |
TET1 (IC50 = 33 μM) TET2 (IC50 = 73 μM)
|
---|---|
ln Vitro |
Bobcat339 hydrochloride (10 μM; 24 hours) fluorescently staining TET enzyme activity in HT-22 cells considerably lowers 5hmC levels [1].
|
ln Vivo |
Bobcat339, a synthetic small molecule that controls TET3 in AgRP neurons, is able to mitigate anorexia nervosa and associated anxiety/depressive behaviors in a murine model. We show that Bobcat339 acts to destabilize TET3 protein in AgRP neurons and that this regulation is conserved in human and mouse cells. We propose that Bobcat339 should be pursued as a therapeutic for anorexia nervosa and perhaps cancer-induced anorexia and associated mood disorders.[2]
|
Enzyme Assay |
Chemiluminescence ELISA. [1]
Procedure adapted from manual. Prepare TBST buffer (1X TBS, pH 8.0, containing 0.05% Tween-20). Dilute 4.0X TET Assay Buffer (TAB) to 1.5X TAB and 1.0X TAB evenly with diluted water. Thaw and dilute (5.0 ng/μl for TET1 and 10 ng/μl for TET2) TET enzyme from kit with 1.0X TAB. Dilute primary antibody 100-fold with blocking buffer. Diluted secondary antibody 1000-fold with blocking buffer. Dilute DMSO inhibitor solutions with 1.0X TAB to wanted concentration (ensure solutions are 5% DMSO). To 96-well plate provided, add 200 μl TBST buffer to each well and incubate at room temperature for 15 min. Remove TBST buffer and add 20 μl 1.5X TAB, 10 μl inhibitor solution, 20 μl diluted TET to each well. For controls, add 10 μl 5% DMSO solution and 20 μl 1.0X TAB. Incubate at room temperature for 2 h. Remove reaction solution and wash 3X with TBST buffer (200, 200, and 100 μl). Add 100 μl blocking buffer 53 μl diluted primary antibody and shake at room temperature for 1 h. Remove diluted primary antibody and wash 3X with TBST buffer (200, 200, and 100 μl). Add 100 μl blocking buffer to each well and shake at room temperature for 10 min. Remove blocking buffer. Add 100 μl diluted secondary antibody. Shake at room temperature for 30 min. Remove diluted secondary antibody and wash 3X with TBST buffer (200, 200, and 100 μl). Add 100 μl blocking buffer to each well and shake at room temperature for 10 min. Remove blocking buffer. Combine horseradish peroxidase (HRP) substrate A and HRP substrate B at 1:1 ratio. Add 100 μl of HRP solution to each well. Immediately, read chemiluminescence[1]. TET Enzyme Computational Models.[1] A solved crystal structure of human TET2 bound to DNA (PDB: 4NM6) was used in the Molecular Operating Environment (MOE) software for all computational analyses.1 A homology model of human TET1 was then produced by aligning its relevant primary sequence with that of TET2 (Figure S1), and then substituting the linear amino acid sequence with an induced fit around the N-oxalylglycine – Fe – methylated dsDNA complex using the Amber 10 EHT force field in the MOE software package. TET2 was crystalized, bound to dsDNA, with N-oxalylglycine, a pan inhibitor of KG-dependent dioxygenase. For both TET1 and TET2 models the nitrogen in N-oxalylglycine, which binds to the KG co-factor site and chelates the catalytic Fe center, was then converted to an sp3 hybridized carbon to produce KG. Then, the dsDNA was removed from the model and the bound 5mC in the active site was used as the starting pose for all cytosine-based inhibitors. |
Cell Assay |
Cell culture[1]
HT22 cells were provided by David Schubert at the Salk Institute. Cells were cultured in Dulbecco’s Modified Eagle Medium supplemented with 10% FBS, 100 U/ml penicillin, and 100 μg/ml streptomycin at 37°C and 5% CO2. HT22 cells were kept at 50-70% confluency and were passaged twice a week. Briefly, culture medium was removed and replaced by 0.05% trypsin. The cells were incubated with trypsin for 5 minutes and 1.5 x volume of culture medium was added to the cell-trypsin suspension. Finally, cells were added at a ratio of 1:10 to fresh culture medium in 35 mm dishes to be used for experiments. Cultured HT22 cells were treated with prepared solutions of Bobcat339 and Bobcat212. 22 μl of compound in DMSO was added to dishes containing 2.2 ml of cell medium, resulting in a 10 μM final concentration of inhibitor and an overall 1% DMSO concentration. Higher concentrations of Bobcat339 suffered from insufficient solubility. Cells were incubated at 37°C and 5% CO2 for 24 hours. DNA extraction[1] Procedure adapted from manual. Remove culture medium from dishes. Add 180 μl buffer ATL to each dish and scrape. Transfer liquid to 1.5 ml microcentrifuge tube. For each sample, add 20 μl proteinase K and immediately mix by pulse vortex. Incubate overnight at 56°C. After incubation, remove from incubator and vortex immediately for 15 seconds. Add 4 μl RNase A to each tube and vortex immediately. Let incubate for 2 mins at RT on bench top. To each sample, add 200 μl Buffer AL and mix thoroughly by vortexing. Add 200 μl ethanol (100%). Immediately mix by vortexing. Pipet each sample mixture into a DNeasy spin column placed in a 2 ml collection tube. Centrifuge at 6000 x g (6000 rcf) for 1 minute. Discard the flow-through and collection tubes. Place each spin column in a new 2 ml collection tube, add 600 μl Buffer AW1, and centrifuge for 1 minute at 6,000 x g. Discard the flow-through and collection tubes. Place the spin column in a new 2 ml collection tube, add 600 μl Buffer AW2, and centrifuge for 3 minutes at 18,213 x g (18,213 rcf). Discard the flow-through and collection tubes, place spin column in new 2 ml collection tube, and centrifuge for another 3 minutes at 18,213 x g (18,213 rcf). Place spin column into final full-description labeled 1.5 mL capped centrifuge tube. Add 22 μl DNase/RNase free water to each spin column as elution buffer and incubate on the benchtop at room temp for 15 minutes. Centrifuge for one minute at 6,000 x g (6,000 rcf = 6,000 x g) and discard spin column. DNA concentrations were determined using a NanoDrop spectrophotometer and samples stored at -20°C. |
Animal Protocol |
Bc Treatment of Mice.[2]
Bobcat339 powder was freshly dissolved in dimethylsulfoxide (DMSO) at a concentration of 50 mg/mL and filtered through a 0.22-μm filter. It was further diluted with 1xPBS to a final concentration of 0.5 mg/mL before injections. Mice were injected i.p. with Bobcat339 at 1 mg/kg, 2.5 mg/kg, or 4 mg/kg. |
References |
Molecular Formula |
C16H13CL2N3O
|
---|---|
Molecular Weight |
334.1999
|
Exact Mass |
333.043
|
Elemental Analysis |
C, 57.50; H, 3.92; Cl, 21.21; N, 12.57; O, 4.79
|
CAS # |
2436747-44-1
|
Related CAS # |
Bobcat339 hydrochloride;2436747-44-1
|
PubChem CID |
138319672
|
Appearance |
Off-white to light yellow solid powder
|
Hydrogen Bond Donor Count |
2
|
Hydrogen Bond Acceptor Count |
1
|
Rotatable Bond Count |
2
|
Heavy Atom Count |
22
|
Complexity |
468
|
Defined Atom Stereocenter Count |
0
|
InChi Key |
ZOMPKMMOPYMRIB-UHFFFAOYSA-N
|
InChi Code |
InChI=1S/C16H12ClN3O.ClH/c17-14-10-20(16(21)19-15(14)18)13-8-4-7-12(9-13)11-5-2-1-3-6-11;/h1-10H,(H2,18,19,21);1H
|
Chemical Name |
1-([1,1'-biphenyl]-3-yl)-4-amino-5-chloropyrimidin-2(1H)-one hydrochloride
|
Synonyms |
Bobcat339 HCl; Bobcat339; Bobcat-339; Bobcat339 hydrochloride; Bobcat 339;
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
DMSO : ~125 mg/mL (~374.03 mM)
H2O : ~0.1 mg/mL (~0.30 mM) |
---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (6.22 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (6.22 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (6.22 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 2.9922 mL | 14.9611 mL | 29.9222 mL | |
5 mM | 0.5984 mL | 2.9922 mL | 5.9844 mL | |
10 mM | 0.2992 mL | 1.4961 mL | 2.9922 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.